#ariba_ref_name	ref_name	gene	var_only	flag	reads	cluster	ref_len	ref_base_assembled	pc_ident	ctg	ctg_len	ctg_cov	known_var	var_type	var_seq_type	known_var_change	has_known_var	ref_ctg_change	ref_ctg_effect	ref_start	ref_end	ref_nt	ctg_start	ctg_end	ctg_nt	smtls_total_depth	smtls_nts	smtls_nts_depth	var_description	free_text
16S.rDNA_WHO_F_01361c	16S.rDNA_WHO_F_01361c	0	1	147	4596	16S	1529	1529	100.0	16S.l15.c4.ctg.1	1973	383.1	1	SNP	n	C1184T	0	.	.	1184	1184	C	1401	1401	C	505	C	288	16S.rDNA_WHO_F_01361c:0:1:C1184T:16S.1184T:E coli C1192T. Resistance to Spectinomycin	.
16S.rDNA_WHO_F_01361c	16S.rDNA_WHO_F_01361c	0	1	147	4596	16S	1529	1529	100.0	16S.l15.c4.ctg.1	1973	383.1	0	HET	.	.	.	C207T	.	207	207	C	424	424	C	371	C,T	165,52	.	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	8170	23S	2890	2890	99.86	23S.l15.c30.ctg.1	3557	378.2	0	.	n	.	0	T695C	SNP	695	695	T	1119	1119	C	471	C,A	275,1	.	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	8170	23S	2890	2890	99.86	23S.l15.c30.ctg.1	3557	378.2	0	.	n	.	0	A1638G	SNP	1638	1638	A	2062	2062	G	424	G,T	258,1	.	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	8170	23S	2890	2890	99.86	23S.l15.c30.ctg.1	3557	378.2	0	.	n	.	0	T1971C	SNP	1971	1971	T	2395	2395	C	353	C,T	210,1	.	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	8170	23S	2890	2890	99.86	23S.l15.c30.ctg.1	3557	378.2	1	SNP	n	C2597T	1	C2597T	SNP	2597	2597	C	3021	3021	T	388	T	232	23S.rDNA_WHO_F_01358c:0:1:C2597T:23S.2597T :E coli C2611T. Low-level resistance to Azithromycin	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	8170	23S	2890	2890	99.86	23S.l15.c30.ctg.1	3557	378.2	1	SNP	n	A2045G	0	.	.	2045	2045	A	2469	2469	A	368	A	209	23S.rDNA_WHO_F_01358c:0:1:A2045G:23S.2045G:E coli A2059G. High-level resistance to Azithromycin	.
folP.WHO_Y_01480c	folP.WHO_Y_01480c	1	1	27	350	folP	855	855	100.0	folP.l15.c4.ctg.1	1239	46.5	1	SNP	p	R229S	1	.	.	685	687	AGC	793	795	AGC	65;65;63	A;G;C	38;37;37	folP.WHO_Y_01480c:1:1:R229S:folP.228S:Resistance to sulphonamides	.
gyrA.WHO_M_01098	gyrA.WHO_M_01098	1	1	27	1052	gyrA	2751	2751	99.85	gyrA.l15.c4.ctg.1	3345	54.1	1	SNP	p	S91F	1	.	.	271	273	TTC	662	664	TTC	79;79;79	T;T;C	51;50;50	gyrA.WHO_M_01098:1:1:S91F:gyrA.91F:Resistance to fluoroquinolones	.
gyrA.WHO_M_01098	gyrA.WHO_M_01098	1	1	27	1052	gyrA	2751	2751	99.85	gyrA.l15.c4.ctg.1	3345	54.1	1	SNP	p	G95N	0	.	.	283	285	GGC	674	676	GGC	85;86;86	G;G;C	53;53;51	gyrA.WHO_M_01098:1:1:G95N:gyrA.95N:Resistance to fluoroquinolones	.
gyrA.WHO_M_01098	gyrA.WHO_M_01098	1	1	27	1052	gyrA	2751	2751	99.85	gyrA.l15.c4.ctg.1	3345	54.1	1	SNP	p	D95G	1	.	.	283	285	GGC	674	676	GGC	85;86;86	G;G;C	53;53;51	gyrA.WHO_M_01098:1:1:D95G:gyrA.95G:Resistance to fluoroquinolones	.
mtrR.WHO_V_01454	mtrR.WHO_V_01454	1	1	27	254	mtrR	633	633	100.0	mtrR.l15.c4.ctg.1	1033	42.6	1	SNP	p	G45D	0	.	.	133	135	GGC	332	334	GGC	67;67;67	G;G;C	39;39;37	mtrR.WHO_V_01454:1:1:G45D:mtrR.45D:Increased efflux of antimicrobials, e.g. macrolides and b-lactam antimicrobials, that are substrates of the MtrCDE efflux pump	.
mtrR_promoter.WHO_F	mtrR_promoter.WHO_F	0	0	531	148	mtrR_promoter	250	250	99.6	mtrR_promoter.l15.c4.ctg.1	885	29.5	0	.	n	.	0	A197.	DEL	197	197	A	502	502	A	59	A	37	.	.
parC.WHO_Y_00247c	parC.WHO_Y_00247c	1	1	27	918	parC	2304	2304	100.0	parC.l15.c4.ctg.1	2639	58.6	1	SNP	p	D86N	0	.	.	256	258	GAC	413	415	GAC	62;62;63	G;A;C	36;31;38	parC.WHO_Y_00247c:1:1:D86N:parC.86N:Resistance to fluoroquinolones	.
parC.WHO_Y_00247c	parC.WHO_Y_00247c	1	1	27	918	parC	2304	2304	100.0	parC.l15.c4.ctg.1	2639	58.6	1	SNP	p	R87I	0	.	.	259	261	CGT	416	418	CGT	61;63;63	C;G;T	35;32;34	parC.WHO_Y_00247c:1:1:R87I:parC.87I:Resistance to fluoroquinolones	.
parC.WHO_Y_00247c	parC.WHO_Y_00247c	1	1	27	918	parC	2304	2304	100.0	parC.l15.c4.ctg.1	2639	58.6	1	SNP	p	R87W	0	.	.	259	261	CGT	416	418	CGT	61;63;63	C;G;T	35;32;34	parC.WHO_Y_00247c:1:1:R87W:parC.87W:Resistance to fluoroquinolones	.
parC.WHO_Y_00247c	parC.WHO_Y_00247c	1	1	27	918	parC	2304	2304	100.0	parC.l15.c4.ctg.1	2639	58.6	1	SNP	p	S87R	1	.	.	259	261	CGT	416	418	CGT	61;63;63	C;G;T	35;32;34	parC.WHO_Y_00247c:1:1:S87R:parC.87R:Resistance to fluoroquinolones	.
parC.WHO_Y_00247c	parC.WHO_Y_00247c	1	1	27	918	parC	2304	2304	100.0	parC.l15.c4.ctg.1	2639	58.6	1	SNP	p	S88P	0	.	.	262	264	TCC	419	421	TCC	62;61;61	T;C;C	37;35;37	parC.WHO_Y_00247c:1:1:S88P:parC.88P:Resistance to fluoroquinolones	.
parE.WHO_F_01528c	parE.WHO_F_01528c	1	1	27	750	parE	1986	1986	100.0	parE.l15.c4.ctg.1	2367	54.4	1	SNP	p	G410V	0	.	.	1228	1230	GGC	1438	1440	GGC	62;63;63	G;G;C	42;43;41	parE.WHO_F_01528c:1:1:G410V:parE.410V:Resistance to fluoroquinolones	.
penA.34.001	penA.34.001	1	1	27	940	penA	1746	1746	100.0	penA.l15.c4.ctg.1	2196	72.0	1	SNP	p	A311V	0	.	.	931	933	GCC	1119	1121	GCC	105;106;102	G;C;C	60;62;58	penA.34.001:1:1:A311V:penA.311V:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.34.001	penA.34.001	1	1	27	940	penA	1746	1746	100.0	penA.l15.c4.ctg.1	2196	72.0	1	SNP	p	I312M	1	.	.	934	936	ATG	1122	1124	ATG	102;102;102	A;T;G	59;60;57	penA.34.001:1:1:I312M:penA.312M:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.34.001	penA.34.001	1	1	27	940	penA	1746	1746	100.0	penA.l15.c4.ctg.1	2196	72.0	1	SNP	p	V316T	1	.	.	946	948	ACC	1134	1136	ACC	107;109;109	A;C,A;C	64;63,1;65	penA.34.001:1:1:V316T:penA.316T:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.34.001	penA.34.001	1	1	27	940	penA	1746	1746	100.0	penA.l15.c4.ctg.1	2196	72.0	1	SNP	p	T316P	0	.	.	946	948	ACC	1134	1136	ACC	107;109;109	A;C,A;C	64;63,1;65	penA.34.001:1:1:T316P:penA.316P:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.34.001	penA.34.001	1	1	27	940	penA	1746	1746	100.0	penA.l15.c4.ctg.1	2196	72.0	1	SNP	p	T483S	0	.	.	1447	1449	ACC	1635	1637	ACC	85;85;86	A;C;C	51;51;52	penA.34.001:1:1:T483S:penA.483S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.34.001	penA.34.001	1	1	27	940	penA	1746	1746	100.0	penA.l15.c4.ctg.1	2196	72.0	1	SNP	p	A501P	0	.	.	1501	1503	GCG	1689	1691	GCG	68;67;67	G;C;G	40;39;39	penA.34.001:1:1:A501P:penA.501P:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.34.001	penA.34.001	1	1	27	940	penA	1746	1746	100.0	penA.l15.c4.ctg.1	2196	72.0	1	SNP	p	A501V	0	.	.	1501	1503	GCG	1689	1691	GCG	68;67;67	G;C;G	40;39;39	penA.34.001:1:1:A501V:penA.501V:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.34.001	penA.34.001	1	1	27	940	penA	1746	1746	100.0	penA.l15.c4.ctg.1	2196	72.0	1	SNP	p	G542S	0	.	.	1624	1626	GGT	1812	1814	GGT	66;65;63	G;G;T	39;38;38	penA.34.001:1:1:G542S:penA.542S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.34.001	penA.34.001	1	1	27	940	penA	1746	1746	100.0	penA.l15.c4.ctg.1	2196	72.0	1	SNP	p	G545S	1	.	.	1633	1635	AGC	1821	1823	AGC	62;68;68	A;G;C	37;40;41	penA.34.001:1:1:G545S:penA.545S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.34.001	penA.34.001	1	1	27	940	penA	1746	1746	100.0	penA.l15.c4.ctg.1	2196	72.0	1	SNP	p	P551S	0	.	.	1651	1653	CCG	1839	1841	CCG	55;54;54	C;C;G	29;28;29	penA.34.001:1:1:P551S:penA.551S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
ponA.WHO_G_00106	ponA.WHO_G_00106	1	1	27	1422	ponA	2397	2397	100.0	ponA.l15.c17.ctg.1	2975	74.1	1	SNP	p	L421P	1	.	.	1261	1263	CCG	1563	1565	CCG	54;54;52	C;C;G	30;32;27	ponA.WHO_G_00106:1:1:L421P:ponA.421P:High-level chromosomally-mediated penicillin resistance	.
porA.NCCP11945	porA.NCCP11945	1	0	531	490	porA	1146	1146	99.91	porA.l15.c4.ctg.1	1571	54.5	0	.	p	.	0	M83fs	FSHIFT	247	247	A	447	447	C	48	C	28	.	.
porB1b.WHO_Y_02277c	porB1b.WHO_Y_02277c	1	1	539	620	porB1b	1038	1038	99.9	porB1b.l15.c4.ctg.1	1509	68.9	0	.	p	.	0	R40Q	NONSYN	118	120	CGG	338	340	CAG	76;73;73	C,A;A,C;G	44,1;41,1;43	.	.
porB1b.WHO_Y_02277c	porB1b.WHO_Y_02277c	1	1	539	620	porB1b	1038	1038	99.9	porB1b.l15.c4.ctg.1	1509	68.9	1	SNP	p	G120K	1	.	.	358	360	AAG	578	580	AAG	91;91;90	A;A;G	56;56;56	porB1b.WHO_Y_02277c:1:1:G120K:porB1b.120K:G101K. Mediates decreased permeability of antimicrobials through the porin PorB1b	.
porB1b.WHO_Y_02277c	porB1b.WHO_Y_02277c	1	1	539	620	porB1b	1038	1038	99.9	porB1b.l15.c4.ctg.1	1509	68.9	1	SNP	p	N121D	0	.	.	361	363	AAC	581	583	AAC	92;92;91	A;A;C	58;57;57	porB1b.WHO_Y_02277c:1:1:N121D:porB1b.121D:A102D. Mediates decreased permeability of antimicrobials through the porin PorB1b	.
porB1b.WHO_Y_02277c	porB1b.WHO_Y_02277c	1	1	539	620	porB1b	1038	1038	99.9	porB1b.l15.c4.ctg.1	1509	68.9	1	SNP	p	A121N	1	.	.	361	363	AAC	581	583	AAC	92;92;91	A;A;C	58;57;57	porB1b.WHO_Y_02277c:1:1:A121N:porB1b.121N:A102N. Mediates decreased permeability of antimicrobials through the porin PorB1b	.
rpoB.WHO_M_02157	rpoB.WHO_M_02157	1	1	27	2428	rpoB	4179	4179	99.98	rpoB.l15.c17.ctg.1	4486	91.6	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
rpsJ.WHO_Y_02241	rpsJ.WHO_Y_02241	1	1	27	216	rpsJ	312	312	100.0	rpsJ.l15.c4.ctg.1	839	46.0	1	SNP	p	V57M	1	.	.	169	171	ATG	381	383	ATG	79;77;79	A;T;G	45;45;45	rpsJ.WHO_Y_02241:1:1:V57M:rpsJ.57M:Chromosomally-mediated resistance to tetracyclines	.
